Pfizer’s 7% Dividend: Temptation with a Warning Label
A 7% yield is a red flag in a market full of green. Pfizer trades at 8.1 times forward earnings-a number that screams “caution.” Earnings are projected to decline 3% annually through 2029. Peers like Johnson & Johnson (2.9%) and Merck (3.9%) offer lower yields but stronger balance sheets. AbbVie’s 3.1% isn’t bad either. These companies trade stability for greed. Pfizer’s dividend is a gamble that management can outwit patent cliffs and pipeline failures. It’s a bet with no guaranteed payout.

